二甲双胍联合阿仑膦酸钠对骨质疏松症合并2型糖尿病的影响

Effect of Metformin Combined with Alendronate on Osteoporosis Combined with Type 2 Diabetes Mellitus

目的探讨对骨质疏松症伴有2型糖尿病患者给予二甲双胍+阿仑膦酸钠治疗后获得的临床效果。方法选取2020年1月—2022年7月莱州市人民医院收治的80例骨质疏松症伴有2型糖尿病患者为研究对象,采用随机数表法分为参照组与研究组,各40例。参照组给予常规控糖+阿仑膦酸钠联合治疗,研究组给予二甲双胍+阿仑膦酸钠联合治疗。比较两组血糖水平[空腹血糖(FPG)、糖化血红蛋白(HbA1c)、餐后2 h血糖(2 hPG)]、血脂水平[三酰甘油(TG)、总胆固醇(TC)以及低密度脂蛋白胆固醇(LDL-C)]及胃肠道不良反应发生率。结果治疗前,两组血糖指标水平比较,差异无统计学意义(P>0.05);治疗后,研究组血糖指标水平低于参照组,差异有统计学意义(P<0.05)。治疗前,两组血脂指标水平比较,差异无统计学意义(P>0.05);治疗后,研究组血脂指标水平低于参照组,差异有统计学意义(P<0.05)。两组胃肠道不良反应发生率比较,差异无统计学意义(P>0.05)。结论临床针对骨质疏松症伴有2型糖尿病患者进行二甲双胍+阿仑膦酸钠治疗,可显著改善血糖、血脂指标,并且不会增加胃肠道不良反应,可促进患者良好预后。

Objective To investigate the clinical effects obtained after giving metformin+alendronate sodium drugs to patients with osteoporosis with type 2 diabetes mellitus.Methods Eighty patients with osteoporosis and type 2 diabetes admitted to Laizhou People's Hospital from January 2020 to July 2022 were selected as the research objects.They were randomly divided into a reference group and a study group,with 40 cases in each group.The reference group was treated with conventional glucose control plus alendronate,while the study group was treated with metformin plus alendronate.The blood glucose level[fasting plasma glucose(FPG),glycosylated hemoglobin(HbA1c),2 h-postprandial blood glucose(2 hPG)],blood lipid level[triglyceride(TG),total cholesterol(TC)and low density lipoprotein cholesterol(LDL-C)]and the incidence of gastrointestinal adverse reactions were compared between the two groups.Results Before treatment,there was no statistically significant difference in blood glucose levels between the two groups(P>0.05);after treatment,the level of blood glucose index in the study group was lower than that in the control group,and the difference was statistically significant(P<0.05).Before treatment,there was no statistically significant difference between the two groups in blood lipid levels(P>0.05);after treatment,the level of blood lipid index in the study group was lower than that in the reference group,and the difference was statistically significant(P<0.05).There was no significant difference in the incidence of gastrointestinal adverse reactions between the two groups(P>0.05).Conclusion Clinical treatment of patients with osteoporosis with type 2 diabetes mellitus was metformin+alendronate,which can improve the glycemic index and lipid index significantly,and does not increase in gastrointestinal adverse effects,and can promote a good prognosis for patients with osteoporosis with type 2 diabetes mellitus.